ABUS
Arbutus Biopharma Corp
$4.87
+0.14 (+2.96%)
At close · Jul 2
Market Cap
$962.01M
Shares
197,537,710
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.87
Open$4.77
Day$4.75–4.96
52W$3.08–5.10
Avg vol 30d2.3M
Short int17.5M · 8.9% float · 14.0d
Short vol44%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+10% above
+
Price vs 50-day avg
+11% above
◦
RSI (14)
67 · neutral
+
MACD trend
positive
+
52-week position
89% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $4 › 200d $4 — 200d above 50d
◦
Institutional flow
1 of 169 funds reported for Jun 30 · net 0 sh shares
◦
Insider flow
No net insider activity over 90 days
−
Short interest
8.87% of float · ▲ +3.2% MoM · 14.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
169 holders — mid 3-yr range
Fundamentals
Excellent
+
Revenue growth
+128% Y/Y
+
EPS growth
+55% Y/Y
−
Free cash flow
$-39.6M
+
Valuation
P/E 5.9 · below peers
+
Balance sheet
net cash $18.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+10% above
Bullish
Price vs 50-day avg
+11% above
Bullish
RSI (14)
67 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
89% · near high
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Flat
1 of 169 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.87% of float · ▲ +3.2% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $5 · 89%
52-wk high $5
vs 200-day avg +10%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| common shares issued and outstanding | 196.9M | Q1 FY2026 | — |
| stock options and unvested restricted stock units outstanding | 9.7M | Q1 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABUS
this stock
Arbutus Biopharma Corp
|
$962.01M | +1.2% | +128.2% | 5.9 | 8.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABUS | +10.4% | +12.0% | +4.7% | +1.5% | +1.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +9.0% | +13.2% | -3.3% | +1.7% | -8.0% |